Patents by Inventor Alexandra Lantermann

Alexandra Lantermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240174637
    Abstract: Provided herein are compounds (e.g., compounds of Formulae (A-I), (B-I), (C-I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs thereof, pharmaceutical compositions thereof, and kits comprising the same. The compounds provided herein are degraders of GRK2 proteins and are therefore useful for, e.g., treating and/or preventing diseases (e.g., cancer) in a subject, for inhibiting tumor growth in a subject, for inhibiting the activity of GRK2 and/or degrading a GRK2 protein in vitro or in vivo, etc. In certain embodiments, the compounds provided herein are selective for GRK2. Also provided herein are methods and synthetic intermediates useful in the preparation of compounds described herein.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 30, 2024
    Inventors: Grazia Piizzi, Eugene L. Piatnitski Chekler, Jonathan Barry Hurov, Alexandra Lantermann, Kiley Marie Couto, Hua Xu, Sourav Sarkar, Bruce Allen Lefker, Ralph P. Robinson, Volodymyr Kysil
  • Publication number: 20230035892
    Abstract: The present invention provides methods for treating cancer using GRK2 inhibitors such as small molecule inhibitors of GRK2 among others. The invention also features compositions containing GRK2 inhibitors, methods of diagnosing patients with GRK2-associated cancer and methods of predicting the response of cancer in a subject to treatment with GRK2 inhibitors.
    Type: Application
    Filed: September 3, 2020
    Publication date: February 2, 2023
    Inventors: Jordi MATA-FINK, Avak KAHVEJIAN, Jonathan Barry HUROV, Alexandra LANTERMANN
  • Publication number: 20230009608
    Abstract: The present disclosure features useful methods to treat cancer, e.g., in a subject in need thereof. The methods described herein are useful in the treatment of disorders associated with GRK2 expression, e.g., cancer or cardiovascular disease. The present disclosure also features compounds (e.g., GRK2 inhibitors), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 26, 2021
    Publication date: January 12, 2023
    Inventors: Grazia Piizzi, Eugene Lvovich Piatnitski Chekler, Jonathan Barry Hurov, Alexandra Lantermann, Kiley Marie Couto, Hua Xu, Sourav Sarker
  • Publication number: 20210283217
    Abstract: Described herein are methods for treating a subject having or at risk of developing an autoimmune or inflammatory condition or an infection by administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: September 16, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Publication number: 20210177823
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer by administering a neuromodulating agent.
    Type: Application
    Filed: September 17, 2020
    Publication date: June 17, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV
  • Publication number: 20210154272
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: October 5, 2020
    Publication date: May 27, 2021
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU
  • Patent number: 10457740
    Abstract: The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: October 29, 2019
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Alexandra Lantermann
  • Publication number: 20190240293
    Abstract: Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
    Type: Application
    Filed: July 25, 2017
    Publication date: August 8, 2019
    Inventors: Erica WEINSTEIN, Jordi MATA-FINK, Avak KAHVEJIAN, Noubar B. AFEYAN, Laura Kristina JEANBART, Alexandra LANTERMANN, Jonathan Barry HUROV, Manuel Andreas FANKHAUSER, Chengyi J. SHU, Eric Franklin ZHU